MP
NKGN

Mangrove Partners’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Mangrove Partners’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-183,800
Closed -$1.79M – 373
2022
Q3 		$1.79M Buy
+183,800
New +$1.79M 0.1% 240

Other funds holding NKGN

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CIM
Cowen Investment Management New York $12M AUM 1.47% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

Mangrove Partners's NKGN Position: Q4 2022 in Review

Mangrove Partners sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q4 2022, closing a stake of 183,800 shares — an estimated $1.79M sold.

Mangrove Partners first reported a position in NKGN in Q3 2022 and held it in 1 quarter. The position peaked at $1.79M in Q3 2022. 59 funds tracked by Wall St. Rank hold NKGN as of Q4 2022.

  • Mangrove Partners reported no remaining NKGen Biotech, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Mangrove Partners sold 183,800 NKGen Biotech, Inc. Common Stock shares in Q4 2022, an estimated $1.79M.
  • Mangrove Partners first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Mangrove Partners's NKGen Biotech, Inc. Common Stock position peaked at $1.79M in Q3 2022.
  • 59 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q4 2022.

Based on Mangrove Partners's 13F filing for Q4 2022, filed 14 Feb 2023.